Caribou Biosciences, Inc. (CRBU) Revenue History
Annual and quarterly revenue from 2019 to present
CRBU Revenue Over Time (2019–2025)
CRBU Revenue Growth History
4 of 6 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- +113.6%
- FY2021 revenue growth
- -22.4%
- FY2022 revenue growth
- +44.3%
- FY2023 revenue growth
- +148.9%
- FY2024 revenue growth
- -71.0%
- FY2025 revenue growth
- +11.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $2.4M | +1.9% |
| Q4 2025 | $3.9M | +89.7% |
| Q3 2025 | $2.2M | +8.6% |
| Q2 2025 | $2.7M | -23.0% |
| Q1 2025 | $2.4M | -3.1% |
| Q4 2024 | $2.1M | -41.6% |
| Q3 2024 | $2.0M | -91.4% |
| Q2 2024 | $3.5M | -7.7% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
CRBU's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
CRBU Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 23, 2026, Caribou Biosciences, Inc. (CRBU) generated trailing twelve-month (TTM) revenue of $11.2 million, reflecting modest growth of +1.9% year-over-year. The most recent quarter (Q1 2026) recorded $2.4 million in revenue, down 39.2% sequentially.
Historical Growth Trajectory
CRBU's 5-year compound annual growth rate (CAGR) stands at -2.0%, indicating revenue contraction over this period. The 3-year CAGR of -7.0% is below the 5-year average, signalling a growth deceleration in recent years. Caribou Biosciences, Inc.'s highest annual revenue of $34.5 million was recorded in 2023.
Revenue by Segment
CRBU's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including EDIT (+8.0% YoY), BEAM (+108.0% YoY), and NTLA (+45.0% YoY) — CRBU has underperformed the peer group in revenue growth. Compare CRBU vs EDIT →
CRBU Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRBUCurrent | $11M | +1.9% | -2.0% | -1220.5% | |
 EDIT | $41M | +8.0% | -14.9% | -245.2% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +45.0% | +3.1% | -651.7% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 FATE | $7M | -52.6% | -26.7% | -2222.4% |
CRBU Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $11.2M | +11.7% | $7.5M | 67.3% | $-136,194,000 | -1220.5% |
| 2024 | $10.0M | -71.0% | $6.1M | 60.7% | $-166,616,000 | -1667.2% |
| 2023 | $34.5M | +148.9% | $31.0M | 89.8% | $-116,059,000 | -336.6% |
| 2022 | $13.9M | +44.3% | $10.2M | 73.7% | $-106,399,000 | -768.2% |
| 2021 | $9.6M | -22.4% | $8.6M | 89.7% | $-66,979,000 | -697.8% |
| 2020 | $12.4M | +113.6% | $-22,064,000 | -178.5% | $-36,124,000 | -292.2% |
| 2019 | $5.8M | - | $5.8M | 100.0% | $-34,305,000 | -592.7% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CRBU — Frequently Asked Questions
Quick answers to the most common questions about buying CRBU stock.
Is CRBU's revenue growth accelerating or slowing?
CRBU revenue growth is slowing. TTM revenue is $11M, up +1.9% year-over-year — below the 5-year CAGR of -2.0%. The deceleration suggests maturing end-markets or increased competition.
What is CRBU's revenue history from 2019 to 2026?
Caribou Biosciences, Inc. (CRBU) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $11M, growing at +1.9% YoY. The 5-year CAGR is -2.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CRBU's long-term revenue growth rate (CAGR)?
Caribou Biosciences, Inc.'s 5-year revenue CAGR of -2.0% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of +1.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CRBU.
Why does CRBU's quarterly revenue fluctuate?
CRBU quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Caribou Biosciences, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is CRBU's revenue distributed by segment?
CRBU reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CRBU's revenue compare to industry peers?
Caribou Biosciences, Inc. (CRBU) with TTM revenue of $11M and +1.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.